Exact Sciences Using MDxHealth's Technology in Colon Cancer Test
January 10, 2011
Exact Sciences Using MDxHealth's Technology in Colon Cancer Test
MDxHealth said that Exact's decision to move forward with the test has triggered a milestone payment of an undisclosed amount. The company is also entitled to royalties on sales of the test once it is commercialized.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- With Top-line Deep-C Trial Data, Exact Sciences Gears Up for FDA and CMS Submissions for Cologuard
April 24, 2013 / Pharmacogenomics Reporter - Rx/Dx, Biomarker Licensing Deals Bolster MDxHealth's Shift to Cancer Diagnostics in 2010
February 23, 2011 / Pharmacogenomics Reporter - Exact Sciences to Use MDxHealth Methylation Biomarker, PCR Tech in Cologuard Test
January 13, 2011 / PCR Insider - Exact Sciences Discusses Benefits of Taking Cologuard through FDA/CMS Parallel Review Pilot
April 3, 2013 / Pharmacogenomics Reporter - Exact Sciences Files Second Module of PMA Application with FDA
February 18, 2013 / GenomeWeb Daily News